[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"exocrine-pancreatic-insufficiency-epi\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:exocrine-pancreatic-insufficiency-epi":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,76,104,130],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100053727","phase-3-comparative-study-to-evaluate-microbial-versus-porcine-pancreatic-enzyme-therapy-in-chronic-pancreatitis-100053727",false,"NCT07697352","Comparative Study to Evaluate Microbial Versus Porcine Pancreatic Enzyme Therapy in Chronic Pancreatitis","A Randomised, Double-Blind, Non-Inferiority Trial Comparing Microbial and Porcine Pancreatic Enzyme Replacement Therapy in Chronic Pancreatitis","NP-PERT","Inclusion Criteria:\n\n* CP fulfilling the M-ANNHEIM criteria 11 with documented PEI (defined as fecal elastase \\\u003C100 µg\u002Fg stool on the background of morphological changes of CP).\n* Willingness to undergo a 2-week wash-out period without pancreatic enzyme therapy before enrolment.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Major psychiatric illness impairing study participation.\n* Systemic illness affecting digestion or study outcomes.\n* Any condition deemed unsuitable for study participation by the investigator.\n* Concurrent acute exacerbation of the CP at the time of screening.","ALL","18 Years",{"count":20,"type":21},134,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Background: Chronic pancreatitis (CP) is a progressive inflammatory disorder causing irreversible pancreatic damage, eventually resulting in pancreatic exocrine insufficiency (PEI). This may lead to malabsorption, malnutrition, weight loss, and impaired quality of life. Pancreatic enzyme replacement therapy (PERT) is the standard treatment for PEI and is predominantly derived from porcine sources. However, religious, ethical, dietary, and supply-related concerns highlight the need for effective non-porcine alternatives. Microbial (fungal)-based pancreatic enzymes have shown promising safety and efficacy in preliminary studies, but evidence in CP remains limited.\n\nObjective: To compare the efficacy and safety of non-porcine microbial (fungal)-based pancreatin with standard porcine-based pancreatin in patients with PEI secondary to CP.\n\nMethods: This investigator-initiated, randomized, double-blind, single-center, non-inferiority trial will enroll 134 adults with CP-associated PEI (defined as having a fecal elastase \\\u003C100 µg\u002Fg). After a two-week washout period, participants will be randomized 1:1 to receive either microbial-based or porcine-based pancreatin for 12 weeks. The primary outcome is the change from baseline in the Pancreatic Exocrine Insufficiency Questionnaire (PEI-Q) score at 12 weeks. Secondary outcomes include nutritional status, anthropometric measures, gastrointestinal symptoms, pain scores, stool consistency, glycaemic parameters, laboratory markers, and quality of life.\n\nDiscussion: This study aims to evaluate whether microbial-based pancreatin is non-inferior to porcine-based therapy and may provide a culturally acceptable and sustainable alternative for managing CP-related PEI.",[27,28],"Pancreatitis, Chronic","Exocrine Pancreatic Insufficiency (EPI)",[30,31,32,33,34],"chronic pancreatitis","exocrine pancreatic insufficiency","Pancreatic enzyme replacement therapy","porcine pancreatic enzyme","microbial (fungal) pancreatic enzyme","NOT_YET_RECRUITING","2026-07-05",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":21},"2026-08",{"date":43,"type":21},"2027-09",{"name":45,"class":46},"Asian Institute of Gastroenterology, India","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100627585","phase-2-phase-2-study-to-assess-the-safety-and-efficacy-of-ang003-100627585","NCT07450547","Phase 2 Study to Assess the Safety and Efficacy of ANG003","A Phase 2, Multicenter, Randomized, Active-controlled Study to Assess the Safety and Efficacy of ANG003 at Two Different Dose Levels in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis","Inclusion Criteria:\n\n1. Male and female subjects aged ≥12 years from the date of informed consent in the US and aged ≥18 years in the EU\n2. Confirmed and documented diagnosis of CF\n3. Diagnosed with severe EPI as defined by a fecal elastase ≤50 μg\u002Fg stool measured at Screening by a central laboratory.\n4. Subject has controlled EPI and taking a stable dose of pancreatic enzyme replacement therapy (PERT) for 90 days prior to Screening.\n5. Adequate nutritional status measured by body mass index (BMI) defined by:\n\n   1. BMI ≥25th percentile for children aged 12-17 years\n   2. BMI ≥18.5 kg\u002Fm2 for ≥18 years of age\n\nExclusion Criteria:\n\n1. History of fibrosing colonopathy or recurring distal intestinal obstructive syndrome within 6 months of Screening.\n2. History of lung or liver transplant, listing for organ transplant or significant bowel resection within the last 6 months. Subjects with a history of resection that does not result in short bowel syndrome are eligible.\n3. Known hypersensitivity or other severe reaction to any ingredient of the investigational product (IP), Creon, or the stool marker (FD\\&C Blue #2).\n4. Any chronic diarrheal illness unrelated to pancreatic insufficiency, actively being treated for small intestinal bacterial overgrowth, requiring use of naso-gastric, J-tube, G-tube, and\u002For enteral feeding for the study duration, Clostridioides difficile infection within 6 months prior to Screening, or severe constipation defined as \\\u003C1 bowel movement\u002Fweek.","12 Years",{"count":56,"type":21},113,[58],"PHASE2","In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called \"enzymes\"), is being investigated as a potential treatment for exocrine pancreatic insufficiency (EPI). People with EPI due to Cystic Fibrosis (CF) may be eligible to participate in this study. The primary objective of this study is to evaluate the safety of ANG003 and see if it works as well compared to Creon, an approved PERT.",[28,61],"Cystic Fibrosis (CF)",[61,63],"EPI","RECRUITING","2026-07-01",{"date":67,"type":39},"2026-07-02",{"date":69,"type":39},"2026-04-24",{"date":71,"type":21},"2027-07",{"name":73,"class":74},"Anagram Therapeutics, Inc.","INDUSTRY",26,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100569257","phase-3-evaluating-the-efficacy-of-relizorb-in-managing-exocrine-pancreatic-insufficiency-in-tube-fed-pancreatitis-patients-100569257","NCT06691893","Evaluating the Efficacy of RELiZORB in Managing Exocrine Pancreatic Insufficiency in Tube-fed Pancreatitis Patients","A Randomized Controlled Trial to Evaluate the Efficacy of Immobilized Lipase (RELiZORB) During Enteral Nutrition in Patients With Exocrine Pancreatic Insufficiency Secondary to Acute Pancreatitis","Inclusion Criteria:\n\n* Patient diagnosed with moderate or severe exocrine pancreatic insufficiency (EPI), as defined using the Pancreatic Exocrine Insufficiency Questionnaire (PEI-Q) symptom score of 1.4 or greater.\n* Patient diagnosed with acute, recurrent acute pancreatitis or subacute pancreatitis. Subacute pancreatitis is defined as recent diagnosis of acute pancreatitis with sequelae of the acute episode including infection, pseudocyst, walled-off pancreatic necrosis.\n* Patient is currently admitted to the hospital at the time of study enrollment.\n* Patient requiring at least 50% of daily caloric and fluid intake through enteral tube feeds.\n* Patient is able and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Patient with chronic pancreatitis\n* Patient is currently intubated and unable to provide consent\n* Patient with active gastrointestinal tract cancer\n* Patient requiring less than 50% of nutritional support at time of enrollment\n* Patient is unable to tolerate any form of enteral nutrition",{"count":84,"type":21},60,[24],"This research aims to improve the management of exocrine pancreatic insufficiency (EPI), a condition that can develop after pancreatitis, a painful inflammation of the pancreas. EPI occurs when the pancreas does not produce enough enzymes to help the body properly digest food. While pancreatic enzyme replacement therapy (PERT) is commonly used to manage EPI symptoms, it can be challenging for people who rely on feeding tubes. RELiZORB, could help these patients by simplifying the delivery of the enzymes they need. However, RELiZORB has only been studied in people with EPI caused by cystic fibrosis, so its effectiveness in pancreatitis patients remains unknown. This study aims to determine whether RELiZORB is effective for individuals requiring feeding tube support after pancreatitis.",[28,88],"Pancreatitis",[31,90,91,92,93],"pancreatitis","RELiZORB","lipase","enteral nutrition","2026-05-12",{"date":96,"type":39},"2026-05-15",{"date":98,"type":39},"2025-03-28",{"date":100,"type":21},"2027-07-15",{"name":102,"class":46},"Massachusetts General Hospital",1,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":127,"locationsCount":129},"100635937","phase-2-a-study-to-evaluate-safety-and-explore-efficacy-of-new-lipase-nhs7108-in-adult-participants-with-exocrine-pancreatic-insufficiency-100635937","NCT07559175","A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.","A Phase 2a, Randomized, Open-Label, Active-Controlled, Crossover Study to Evaluate Safety and Explore Efficacy of Different Doses of New Lipase NHS7108 Administered Orally in Participants With Exocrine Pancreatic Insufficiency- EPIC","EPIC","Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply:\n\n1. Participant is a male or female between 18 to 85 years of age, inclusive, at the time of signing the informed consent.\n2. Participants with clinically confirmed\\* chronic established (not due to a transient clinical diagnosis, i.e., acute pancreatitis) EPI and with a clinical indication for PERT.\n3. CFA off PERT of \\\u003C80% at screening\n4. Normal body mass index (BMI) by age and sex to ensure participant's EPI is adequately controlled in the opinion of the investigator (BMI of at least 17.0 and no greater than 35.0 kg\u002Fm²)\n5. Standard-of-care medications are allowed (antibiotics, mucolytic agents, aerosols, antacids), if on stable doses for at least 1 month prior to baseline CFA and CNA assessments and must not be altered in dose or stopped during the study.\n6. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators are allowed if on stable doses for at least 3 months prior to randomization. Participants should not start taking CFTR modulators during the duration of the study.\n7. Contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\n   Male Participants:\n   * Non-sterilized male participants are eligible to participate if they agree to one of the following starting at screening and continuing throughout the clinical study period, and until the end-of-study safety follow-up: Must agree to stay abstinent (where abstinence is the preferred and usual lifestyle of the participant), OR male participants with a female partner of childbearing potential must agree to use highly effective contraception consisting of 2 forms of birth control (1 of which must be a barrier method). Male participants with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile penetration. These requirements also apply to participants in a same sex relationship.\n   * Male participants must agree not to donate sperm starting at screening and continuing throughout the clinical study period, and until the end-of-study safety follow-up.\n\n   Female Participants:\n   * Female participants of childbearing potential (as defined in Appendix 4) are eligible to participate if they meet the following criteria: Agree not to become pregnant during the clinical study period and until the end-of-study safety follow-up. Have a negative serum pregnancy test at screening and a negative urine pregnancy test at Day 1. If heterosexually active, must agree to consistently use a form of highly effective birth control, in combination with a barrier method starting at screening and continuing throughout the clinical study period, and until the end-of-study safety follow-up, OR agree to stay abstinent (where abstinence is the preferred and usual lifestyle of the participant), starting at screening and continuing throughout the clinical study period, and until the end-of-study safety follow-up. These requirements do not apply to participants in a same sex relationship.\n   * Female participants of nonchildbearing potential are eligible to participate if one of the following conditions apply: Must have a confirmed clinical history of sterility (documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy, as confirmed by review of the participant's medical records, medical examination, or medical history interview). Must be postmenopausal as defined as: amenorrhea for at least 1 year prior to screening and a laboratory confirmed serum follicle-stimulating hormone (FSH) level ≥ 40 mIU\u002FmL. Female participants on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use 1 of the non-estrogen hormonal highly effective contraception methods from screening until at and continuing throughout the clinical study period, and until the end-of-study safety follow-up if they wish to continue their HRT during the study.\n   * Female participants must agree not to donate ova starting at screening and continuing throughout the clinical study period, and until the end-of-study safety follow-up.\n   * For WOCBP only, serum pregnancy test will be performed at screening and urine pregnancy tests will be performed at the timepoints outlined in the SoA.\n   * The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.\n8. Participants are capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n9. Participants agree not to participate in another interventional study while participating in the study.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n1. Female participants who are breastfeeding at the time of screening.\n2. Previous GI surgery, except for non-invasive neonatal or early childhood procedures such as correction of hypertrophic pyloric stenosis, surgical correction of Meckel's diverticulum, volvulus, or intestinal intussusception. Hernia repair, appendectomy, cesarean section, tubal ligation, hysterectomy, polypectomy, hemorrhoidectomy, or cholecystectomy are allowed if performed at least 2 years before randomization and have no impact on intestinal transit or absorption.\n3. Participants on enteral feeding.\n4. Participants with celiac disease.\n5. Known allergy or adverse reaction history to any component of NHS7108, Zenpep®, omega-3 oil, and\u002For to any other product administered during the study, including the blue dye.\n6. Concurrent clinically significant, at the discretion of the Investigator, hematological, renal, endocrine, pulmonary, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, and seasonal allergies and childhood asthma) or any other disorder that in the opinion of the Investigator may put the participant at greater safety risk, influence response to study intervention, or interfere with study assessments.\n7. Concurrent conditions having a clinically significant impact on GI motility function, with the exception of pancreatic insufficiency due to pancreatectomy or CP.\n8. Any significant clinical\u002Flaboratory\u002Fradiological sign of unstable or unexpectedly deteriorating respiratory disease during the study duration, at the discretion of the Investigator.\n9. Omega-3 supplements are prohibited during all the study periods and should be stopped at least 7 days prior to the baseline off-treatment fat absorption assessments.\n10. Participants starting new medications or changing dose within 1 month before baseline off-treatment screening assessments.\n11. Acute use of oral or intravenous antibiotics within 2 weeks prior to the first dose of study intervention.\n12. Treatment with any investigational drug or device\u002Ftreatment within the 30 days or 5 half-lives of the drug (whichever is longer) prior to first dose of study intervention.\n13. Participant has any clinically significant abnormalities in hematology, coagulation, clinical chemistry, or urinalysis at screening as judged by the Investigator OR as detailed below:\n\n    * Estimated glomerular filtration rate \\\u003C 60 mL\u002Fmin at screening visit.\n    * Total bilirubin \\> 1.5 × upper limit of normal (ULN) at screening visit.\n    * Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 2 × ULN at screening visit.\n14. Positive human immunodeficiency virus (HIV) antibody test.\n15. Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study intervention.\n16. Positive hepatitis C virus (HCV) antibody test result at screening or within 3 months prior to first dose of study intervention AND positive on reflex to hepatitis C RNA test.\n17. Concurrent drug or alcohol addiction that in the opinion of the Investigator would preclude participation and compliance with the study procedures.","85 Years",{"count":114,"type":21},66,[58],"The purpose of this study is to measure the safety and explore the efficacy of 4 different doses of the new lipase NHS7108 in participants with EPI. In this study, all participants will take NHS7108 daily for 14 days and a matching dose of standard-of-care, pancrelipase (Zenpep®) for 14 days according to Treatment Sequence assignment. Both NHS7108 and Zenpep® are oral capsules that will be taken with each of the daily 3 meals and 2 snacks. Participants will interrupt all of their usual pancrelipase\u002Fpancreatin treatment for up to 8 days during screening and for the entire 2 treatment periods, where participants will take either the new lipase NHS7108 or a matching dose of the standard-of-care pancrelipase (Zenpep®). Participants will be asked to stay in a setting that allows controlled diet and 72-hour stool collection for approximately 7 days during the screening period and again for approximately 7 days at the end of each treatment period. During these 3 supervised periods, participants will receive a standardized diet with a predefined amount of fat and protein, stools will be collected in special containers and during the last day of the treatment period, blood samples will be obtained to measure fat absorption. These are essential to ensure valid assessment of participants' fat and protein absorption. Outside the 3 supervised periods, participants will be provided with guidelines and recommendations to create their own home-controlled meals and snacks according to their preferences for the remainder of the study duration.\n\nNumber of Participants:\n\nThe aim is to have 56 participants completing the study. Assuming approximately 14% drop-out rate, approximately 66 participants will be randomized to study intervention.\n\nStudy Arms and Duration:\n\nThe total study duration for each participant will be about 100 days (approximately 14 weeks), including:\n\n* A screening period of up to approximately 28 days (might be extended up to a total of 56 days) prior to the first dose administration.\n* A crossover treatment period (2 treatment periods: approximately 14 days each, with no washout in between). For each treatment period, study intervention will be administered 5 times a day (with 3 main meals and 2 snacks). After completion of Treatment Period 1, the participant will receive and start the new treatment for Treatment Period 2.\n* An end of treatment\u002Fearly discontinuation visit within approximately 7 days of the last study intervention dose.\n* An end-of-study safety follow-up visit at 14 (±2) days after the last dose administration.\n\nVery low dose group: 10 mg NHS7108 (approximately 25,000 LU)\u002Fmain meal and snack; 25,000 LU Zenpep\u002Fmain meal and snack (50 mg NHS7108 \\[approximately 125,000 LU\\] per day; 125,000 LU Zenpep per day)\n\nLow dose group: 20 mg NHS7108 (approximately 50,000 LU)\u002Fmain meal and 10 mg NHS7108 (approximately 25,000 LU)\u002Fsnack; 50,000 LU Zenpep\u002Fmain meal and 25,000 LU Zenpep\u002Fsnack (80 mg NHS7108 \\[approximately 200,000 LU\\] per day; 200,000 LU Zenpep per day)\n\nMedium dose group: 40 mg NHS7108 (approximately 100,000 LU)\u002Fmain meal and 20 mg (approximately 50,000 LU) NHS7108\u002Fsnack; 100,000 LU Zenpep\u002Fmain meal and 50,000 LU Zenpep\u002Fsnack (160 mg \\[approximately 400,000 LU\\] NHS7108 per day; 400,000 LU Zenpep per day)\n\nHigh dose group: 60 mg NHS7108 (approximately 150,000 LU)\u002Fmain meal and 30 mg NHS7108 (approximately 75,000 LU)\u002Fsnack; 150,000 LU Zenpep\u002Fmain meal and 75,000 LU Zenpep\u002Fsnack (240 mg NHS7108 \\[approximately 600,000 LU\\] per day; 600,000 LU Zenpep per day).\n\nThe dose for participants \\\u003C 60 kg who are assigned to the high dose group will need to be weight-adjusted to ensure that they receive no more than 10,000 LU\u002Fkg\u002Fday.",[28,61,118,119],"Pancreatic Enzyme Abnormality","Pancreatic Diseases",[110],"2026-04-23",{"date":123,"type":39},"2026-04-30",{"date":125,"type":21},"2026-04",{"date":43,"type":21},{"name":128,"class":74},"Aimmune Nestlé Health Science US R&D, LLC",30,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":141,"phases":4,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":103},"100632380","assessment-of-pancreatic-dysfunction-in-patients-with-type-2-diabetes-100632380","NCT07512934","Assessment of Pancreatic Dysfunction in Patients With Type 2 Diabetes","Integrated Assessment of Pancreatic Dysfunction in Patients With Type 2 Diabetes: a Cross-sectional Study Protocol","T3cDM-AKT","Inclusion Criteria:\n\n* • adult patients of Kazakh nationality aged 18 to 74 years\n* diagnosis of T2DM established according to ADA criteria and documented in medical records\n* disease duration ≤5 years\n* absence of ketoacidosis episodes within the last 6 months\n\nExclusion Criteria:\n\n* positive anti-glutamic acid decarboxylase antibodies (anti-GAD65);\n* acute or chronic infections affecting metabolic status within the previous 4 weeks;\n* any history of malignant neoplasms;\n* pregnancy or lactation;\n* previously diagnosed type 1 diabetes mellitus or other specific types of diabetes;\n* severe decompensated chronic diseases;\n* conditions associated with systemic fibrosis (e.g., liver cirrhosis or autoimmune diseases);\n* refusal to participate.","74 Years",{"count":140,"type":21},310,"OBSERVATIONAL","The goal of this observational study is to better understand how the pancreas works in adults with type 2 diabetes. The study focuses on both hormone production (endocrine function) and digestive function (exocrine function) of the pancreas.\n\nThe main questions it aims to answer are:\n\n* Can problems with the pancreas help identify a different type of diabetes called pancreatogenic diabetes?\n* How are blood markers and pancreas structure related to pancreatic function?\n\nParticipants will:\n\n* Have blood tests to measure glucose, insulin, and other markers\n* Provide a stool sample to assess digestive function\n* Undergo an ultrasound examination of the pancreas\n* Answer questions about digestive symptoms\n\nThe study will take place during a single visit in outpatient clinics.",[144,145,28],"Pancreatogenic Diabetes Mellitus","Type 2 Diabetes Mellitus (T2DM)",[147,148,149,150,151,152,153,154,155],"Type 3c diabetes","Pancreatogenic diabetes","Fecal elastase-1","TGF-beta1","Adiponectin","IL-1 receptor antagonist","Pancreatic ultrasound","PEI-Q","Type 2 Diabetes Mellitus","2026-04-02",{"date":158,"type":39},"2026-04-06",{"date":160,"type":39},"2025-07-07",{"date":162,"type":21},"2026-12-01",{"name":164,"class":46},"West Kazakhstan Marat Ospanov Medical University"]